Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

Video

In Partnership With:

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist and associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Idecabtagene vicleucel (ide-cel; bb2121) and JNJ-4528 are similar in the way they target BCMA and intracellularly signal 4-1BB, Shah explains. This could be very beneficial to patients with multiple myeloma as BCMA is uniformly expressed on ​myeloma plasma cells.

However, these products differ in terms of structure​, Shah adds. For example, the BCMA-directed component of ide-cel attaches to 2 different parts of the target.

Notably, recent findings suggest that ​even patients ​with low levels of BCMA can respond to BCMA-directed CAR T-cell therapy, Shah concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic